| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H23BrFNO2 |
| Molecular Weight | 420.315 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3
InChI
InChIKey=RKLNONIVDFXQRX-UHFFFAOYSA-N
InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
Bromperidol (marketed as Bromidol, Bromodol) is a butyrophenone derivative. It is a potent and long-acting neuroleptic, used as an antipsychotic in the treatment of schizophrenia. It was discovered at Janssen Pharmaceutica in 1966. Bromperidol is a bromine analog of Haloperidol hydrochloride (sc-203593) which functions as a D2DR (dopamine D2 receptor) antagonist. Studies suggest that cytochrome CYP3A4 catalyzes the dehydration of Bromperidol and N-dealkylation of Bromperidol. In addition, CYP3A4 can oxidize N-dealkylated Bromperidol back into Bromperidol. Alternately, Bromperidol antagonizes the Neuroendocrine DA receptors which regulate hypothalamic LH-RH release.
Originator
Approval Year
Doses
AEs
PubMed
Patents
Sample Use Guides
Oral Schizophrenia:
Adult: 1-15 mg daily, up to 50 mg daily.
Intramuscular Schizophrenia:
Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj.
Intramuscular Psychoses:
Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj.
Oral Psychoses:
Adult: 1-15 mg daily, up to 50 mg daily.
Route of Administration:
Other
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
